CA2796942A1 - Method for diagnosing melanocytic proliferations - Google Patents
Method for diagnosing melanocytic proliferations Download PDFInfo
- Publication number
- CA2796942A1 CA2796942A1 CA2796942A CA2796942A CA2796942A1 CA 2796942 A1 CA2796942 A1 CA 2796942A1 CA 2796942 A CA2796942 A CA 2796942A CA 2796942 A CA2796942 A CA 2796942A CA 2796942 A1 CA2796942 A1 CA 2796942A1
- Authority
- CA
- Canada
- Prior art keywords
- staining
- sac
- diagnosis
- nevus
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 18
- 230000035755 proliferation Effects 0.000 title claims abstract 9
- 238000010186 staining Methods 0.000 claims abstract 30
- 102100032157 Adenylate cyclase type 10 Human genes 0.000 claims abstract 24
- 101000775498 Homo sapiens Adenylate cyclase type 10 Proteins 0.000 claims abstract 24
- 238000003745 diagnosis Methods 0.000 claims abstract 12
- 210000002752 melanocyte Anatomy 0.000 claims abstract 7
- 238000012758 nuclear staining Methods 0.000 claims abstract 6
- 102000007999 Nuclear Proteins Human genes 0.000 claims abstract 2
- 108010089610 Nuclear Proteins Proteins 0.000 claims abstract 2
- 238000012303 cytoplasmic staining Methods 0.000 claims abstract 2
- 230000002962 histologic effect Effects 0.000 claims abstract 2
- 206010027145 Melanocytic naevus Diseases 0.000 claims 6
- 208000007256 Nevus Diseases 0.000 claims 6
- 208000004649 neutrophil actin dysfunction Diseases 0.000 claims 5
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 claims 4
- 208000030457 superficial spreading melanoma Diseases 0.000 claims 4
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 claims 3
- 206010062805 Dysplastic naevus Diseases 0.000 claims 3
- 206010023256 Juvenile melanoma benign Diseases 0.000 claims 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000021039 metastatic melanoma Diseases 0.000 claims 3
- 206010024218 Lentigo maligna Diseases 0.000 claims 2
- 206010029488 Nodular melanoma Diseases 0.000 claims 2
- 206010000583 acral lentiginous melanoma Diseases 0.000 claims 2
- 208000011080 lentigo maligna melanoma Diseases 0.000 claims 2
- 201000000032 nodular malignant melanoma Diseases 0.000 claims 2
- 206010060999 Benign neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a method for diagnosing a melanocytic proliferation in a subject comprising staining a sample of lesional melanocytes with an antibody against soluble adenylyl cyclase (sAC) and interpreting the sAC staining pattern, which is associated with a diagnosis of a melanocytic proliferation. The sAC staining pattern, which is complex, is discriminatory and distinctive according to the nature of the melanocytic proliferation. The sAC staining pattern comprises one or more of dot-like Golgi staining, broad granular Golgi staining, diffuse cytoplasmic staining, nucleolar staining, incomplete granular nuclear staining, and pan-nuclear staining. The method of the invention is particularly useful in confirming or disaffirming a diagnosis reached through conventional histologic examination of a sample. Additionally, the invention provides a kit for use in interpreting melanocytic proliferations.
Claims (15)
1. A method for diagnosing a melanocytic proliferation in a subject comprising:
(a) obtaining a sample of lesional melanocytes from a subject, (b) staining the sample with an antibody against soluble adenylyl cyclase (sAC) to establish a sAC staining pattern, and (c) interpreting the sAC staining pattern, wherein the sAC staining pattern is associated with a diagnosis of a melanocytic proliferation in the subject.
(a) obtaining a sample of lesional melanocytes from a subject, (b) staining the sample with an antibody against soluble adenylyl cyclase (sAC) to establish a sAC staining pattern, and (c) interpreting the sAC staining pattern, wherein the sAC staining pattern is associated with a diagnosis of a melanocytic proliferation in the subject.
2. The method of claim 1, wherein the sAC staining pattern comprises one or more staining patterns selected from the group consisting of:
(a) dot-like Golgi staining, (b) broad granular Golgi staining, (c) diffuse cytoplasmic staining, (d) nucleolar staining, (e) incomplete granular nuclear staining, and (f) pan-nuclear staining.
(a) dot-like Golgi staining, (b) broad granular Golgi staining, (c) diffuse cytoplasmic staining, (d) nucleolar staining, (e) incomplete granular nuclear staining, and (f) pan-nuclear staining.
3. The method of claim 2, wherein the sAC staining pattern is indicative of a diagnosis selected from the group consisting of benign nevus, benign capsular nevus, atypical nevus of special sites, dysplastic nevus, conventional atypical Spitz tumor, superficial atypical Spitz tumor, borderline deep penetrating nevus-like lesion, nevoid borderline tumor, lentigo maligna melanoma, acral lentiginous melanoma, superficial spreading melanoma, nodular melanoma, and metastatic melanoma.
4. The method of claim 3, wherein the sAC staining pattern comprises:
(a) dot-like Golgi staining in more than 25% of lesional melanocytes and/or (b) pan-nuclear staining in 0-25% of lesional melanocytes, which sAC staining pattern is indicative of a diagnosis of benign nevus, benign capsular nevus, atypical nevus of special sites, or dysplastic nevus.
(a) dot-like Golgi staining in more than 25% of lesional melanocytes and/or (b) pan-nuclear staining in 0-25% of lesional melanocytes, which sAC staining pattern is indicative of a diagnosis of benign nevus, benign capsular nevus, atypical nevus of special sites, or dysplastic nevus.
5. The method of claim 3, wherein the sAC staining pattern comprises:
(a) dot-like Golgi staining in 0-25% of lesional melanocytes and/or (b) pan-nuclear staining in more than 25% of lesional melanocytes, which sAC staining pattern is indicative of a diagnosis of lentigo maligna melanoma, acral lentiginous melanoma, superficial spreading melanoma, nodular melanoma, or metastatic melanoma.
(a) dot-like Golgi staining in 0-25% of lesional melanocytes and/or (b) pan-nuclear staining in more than 25% of lesional melanocytes, which sAC staining pattern is indicative of a diagnosis of lentigo maligna melanoma, acral lentiginous melanoma, superficial spreading melanoma, nodular melanoma, or metastatic melanoma.
6. The method of claim 2, wherein the sAC staining pattern is used to distinguish between a benign neoplasm and a malignant neoplasm.
7. The method of claim 2, wherein the sAC staining pattern is used to distinguish between a diagnosis of dysplastic nevus and a diagnosis of superficial spreading melanoma.
8. The method of claim 2, wherein the sAC staining pattern is used to distinguish between a diagnosis of superficial atypical Spitz tumor and a diagnosis of superficial spreading melanoma.
9. The method of claim 2, wherein the sAC staining pattern is used to distinguish between a diagnosis of benign capsular nevus and a diagnosis of metastatic melanoma.
10. The method of any one of claims 1-9, wherein the antibody is a monoclonal antibody.
11. The method of claim 10, wherein the monoclonal antibody is R5, R6.2, R7, R14, R21, R33, R37, R40, R41, R47.1, R52, R53, R54, or R59.
12. The method of any one of claims 1-9, wherein the antibody is a polyclonal antibody.
13. The method of any one of claims 1-12, wherein the subject is a human.
14. The method of any of claims 1-13, wherein the method is used in conjunction with conventional histologic examination of the sample.
15. A kit for diagnosing a melanocytic proliferation in a subject comprising:
(a) an antibody against soluble adenylyl cyclase (sAC) and (b) instructional material for staining a sample of lesional melanocytes from a subject to provide a sAC staining pattern and diagnosing a melanocytic proliferation in the subject by interpreting the sAC staining pattern of the sample.
(a) an antibody against soluble adenylyl cyclase (sAC) and (b) instructional material for staining a sample of lesional melanocytes from a subject to provide a sAC staining pattern and diagnosing a melanocytic proliferation in the subject by interpreting the sAC staining pattern of the sample.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32617410P | 2010-04-20 | 2010-04-20 | |
| US61/326,174 | 2010-04-20 | ||
| PCT/US2011/031466 WO2011133327A1 (en) | 2010-04-20 | 2011-04-06 | Method for diagnosing melanocytic proliferations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2796942A1 true CA2796942A1 (en) | 2011-10-27 |
| CA2796942C CA2796942C (en) | 2019-09-24 |
Family
ID=43928049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2796942A Expired - Fee Related CA2796942C (en) | 2010-04-20 | 2011-04-06 | Method for diagnosing melanocytic proliferations |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8859213B2 (en) |
| EP (1) | EP2561355B1 (en) |
| BR (1) | BR112012026837B1 (en) |
| CA (1) | CA2796942C (en) |
| IL (1) | IL222550A (en) |
| WO (1) | WO2011133327A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011031879A2 (en) * | 2009-09-09 | 2011-03-17 | Oregon Health & Science University | Automated detection of melanoma |
| CN104981696B (en) | 2012-12-11 | 2017-11-24 | 康奈尔大学 | Diagnosis and the method for the treatment of prostate cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| WO1989012690A1 (en) | 1988-06-13 | 1989-12-28 | American Biogentic Sciences, Inc. | Method for the production of monoclonal antibodies utilizing a germfree animal |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6544768B1 (en) * | 1999-05-11 | 2003-04-08 | Cornell Research Foundation, Inc. | Mammalian soluble adenylyl cyclase |
| WO2005070419A1 (en) * | 2004-01-21 | 2005-08-04 | Cornell Research Foundation, Inc. | Chemical inhibitors of soluble adenylyl cyclase (sac) |
| EP2518509B1 (en) | 2008-03-05 | 2014-05-14 | The Regents of the University of California | Molecular prognosis and classification of malignant melanoma based upon markers selected from the list consisting of RGS1, NCOA3, SPP1, PHIP. |
-
2011
- 2011-04-06 WO PCT/US2011/031466 patent/WO2011133327A1/en active Application Filing
- 2011-04-06 BR BR112012026837A patent/BR112012026837B1/en active IP Right Grant
- 2011-04-06 CA CA2796942A patent/CA2796942C/en not_active Expired - Fee Related
- 2011-04-06 EP EP11714905.4A patent/EP2561355B1/en not_active Not-in-force
- 2011-04-06 US US13/642,475 patent/US8859213B2/en active Active
-
2012
- 2012-10-18 IL IL222550A patent/IL222550A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2796942C (en) | 2019-09-24 |
| BR112012026837B1 (en) | 2020-04-07 |
| IL222550A0 (en) | 2012-12-31 |
| EP2561355B1 (en) | 2014-06-18 |
| WO2011133327A1 (en) | 2011-10-27 |
| EP2561355A1 (en) | 2013-02-27 |
| IL222550A (en) | 2016-02-29 |
| US20130065246A1 (en) | 2013-03-14 |
| AU2011243118A1 (en) | 2012-11-15 |
| BR112012026837A2 (en) | 2016-11-29 |
| US8859213B2 (en) | 2014-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wong et al. | The presentation, pathology, and current management strategies of cutaneous metastasis | |
| Tseng et al. | Tumor location predicts survival in cutaneous head and neck melanoma | |
| Newman et al. | Fluorescence in situ hybridization as a tool for microstaging in malignant melanoma | |
| WO2006133460A3 (en) | Methods for diagnosing and treating breast cancer based on a her/er ratio | |
| DE69907153D1 (en) | CANCER TREATMENT | |
| WO2008103645A3 (en) | Prostate cancer and melanoma antigens | |
| EP1755659A4 (en) | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation | |
| CA2796942A1 (en) | Method for diagnosing melanocytic proliferations | |
| EP3159695A3 (en) | Methods for diagnosing pancreatic cancer | |
| GB2430267A (en) | Detecting melanoma by electron paramagnetic resonance | |
| Vyas et al. | Cutaneous manifestations associated with melanoma | |
| Liu et al. | Prognostic factors in patients with node-negative gastric cancer: a single center experience from China | |
| Mandal et al. | Malignant transformation in a mature teratoma with metastatic deposits in the omentum: a case report | |
| Takenouchi et al. | Long‐term prognosis after surgical excision of basal cell carcinoma: A single institutional study in J apan | |
| Guida et al. | Non-invasive imaging for skin cancers—the European experience | |
| Li et al. | Risk factors for locoregional recurrence after postmastectomy radiotherapy in breast cancer patients with four or more positive axillary lymph nodes | |
| WO2006023382A3 (en) | Collagen vi and cancer | |
| TW200517122A (en) | Antibodies specific for cancer associated antigen SM5-1 and uses thereof | |
| WO2004063711A3 (en) | Use of adiponectin to diagnose and treat malignancy | |
| Pižem et al. | Melanocytic lesions with eczematous reaction (M eyerson's phenomenon)–a histopathologic analysis of 64 cases | |
| Mozzillo et al. | Sentinel lymph node biopsy in patients with cutaneous melanoma: outcome after 3-year follow-up | |
| Marrazzo et al. | Localization of sentinel lymph node in breast cancer. A prospective study | |
| Shirazi et al. | Pigmented Pre-malignant and Malignant Lesions of Skin with Special Reference to Atypical Presentations | |
| Li et al. | Edge Recognition on Terahertz Pulse Images of Cutaneous Malignant Melanoma | |
| Namkoong et al. | Large dermal non neural granular cell tumor on the surgical wound site |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160324 |
|
| MKLA | Lapsed |
Effective date: 20220406 |